Logo image of IBT.CA

IBEX TECHNOLOGIES INC (IBT.CA) Stock Fundamental Analysis

TSX-V:IBT - TSX Venture Exchange - CA4489375085 - Common Stock - Currency: CAD

1.44  0 (0%)

Fundamental Rating

6

Overall IBT gets a fundamental rating of 6 out of 10. We evaluated IBT against 24 industry peers in the Biotechnology industry. IBT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IBT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year IBT was profitable.
IBT had a positive operating cash flow in the past year.
Of the past 5 years IBT 4 years were profitable.
IBT had a positive operating cash flow in 4 of the past 5 years.
IBT.CA Yearly Net Income VS EBIT VS OCF VS FCFIBT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1M -1M 2M 3M

1.2 Ratios

Looking at the Return On Assets, with a value of 22.64%, IBT belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
IBT has a Return On Equity of 28.25%. This is amongst the best in the industry. IBT outperforms 100.00% of its industry peers.
IBT's Return On Invested Capital of 6.83% is amongst the best of the industry. IBT outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IBT is significantly below the industry average of 19.14%.
Industry RankSector Rank
ROA 22.64%
ROE 28.25%
ROIC 6.83%
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
IBT.CA Yearly ROA, ROE, ROICIBT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

1.3 Margins

IBT's Profit Margin of 51.82% is amongst the best of the industry. IBT outperforms 100.00% of its industry peers.
IBT's Profit Margin has improved in the last couple of years.
The Operating Margin of IBT (19.58%) is better than 100.00% of its industry peers.
IBT's Operating Margin has improved in the last couple of years.
The Gross Margin of IBT (71.29%) is better than 88.00% of its industry peers.
IBT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 19.58%
PM (TTM) 51.82%
GM 71.29%
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
IBT.CA Yearly Profit, Operating, Gross MarginsIBT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IBT is creating some value.
IBT has less shares outstanding than it did 1 year ago.
IBT has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for IBT has been reduced compared to a year ago.
IBT.CA Yearly Shares OutstandingIBT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
IBT.CA Yearly Total Debt VS Total AssetsIBT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

An Altman-Z score of 4.22 indicates that IBT is not in any danger for bankruptcy at the moment.
The Altman-Z score of IBT (4.22) is better than 92.00% of its industry peers.
IBT has a debt to FCF ratio of 1.60. This is a very positive value and a sign of high solvency as it would only need 1.60 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.60, IBT belongs to the top of the industry, outperforming 96.00% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that IBT is not too dependend on debt financing.
IBT has a Debt to Equity ratio (0.10) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 1.6
Altman-Z 4.22
ROIC/WACC0.89
WACC7.68%
IBT.CA Yearly LT Debt VS Equity VS FCFIBT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M

2.3 Liquidity

IBT has a Current Ratio of 5.08. This indicates that IBT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IBT (5.08) is better than 76.00% of its industry peers.
A Quick Ratio of 4.97 indicates that IBT has no problem at all paying its short term obligations.
IBT has a better Quick ratio (4.97) than 72.00% of its industry peers.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 4.97
IBT.CA Yearly Current Assets VS Current LiabilitesIBT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

IBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 139.95%, which is quite impressive.
IBT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 59.15% yearly.
The Revenue has decreased by -0.82% in the past year.
IBT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.64% yearly.
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBT.CA Yearly Revenue VS EstimatesIBT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.00, which indicates a very decent valuation of IBT.
Based on the Price/Earnings ratio, IBT is valued cheaper than 100.00% of the companies in the same industry.
IBT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.30.
Industry RankSector Rank
PE 9
Fwd PE N/A
IBT.CA Price Earnings VS Forward Price EarningsIBT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

IBT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBT is cheaper than 96.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IBT indicates a rather cheap valuation: IBT is cheaper than 92.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 34.47
EV/EBITDA 14.11
IBT.CA Per share dataIBT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

IBT has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBEX TECHNOLOGIES INC

TSX-V:IBT (4/5/2024, 7:00:00 PM)

1.44

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-15 2021-12-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap35.30M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9
Fwd PE N/A
P/S 4.53
P/FCF 34.47
P/OCF 15.87
P/B 2.47
P/tB 2.47
EV/EBITDA 14.11
EPS(TTM)0.16
EY11.11%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY2.9%
OCF(TTM)0.09
OCFY6.3%
SpS0.32
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.64%
ROE 28.25%
ROCE 9.74%
ROIC 6.83%
ROICexc 15.45%
ROICexgc 15.45%
OM 19.58%
PM (TTM) 51.82%
GM 71.29%
FCFM 13.13%
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
ROICexc(3y)24.64%
ROICexc(5y)N/A
ROICexgc(3y)24.64%
ROICexgc(5y)N/A
ROCE(3y)13.2%
ROCE(5y)N/A
ROICexcg growth 3Y5.1%
ROICexcg growth 5YN/A
ROICexc growth 3Y5.1%
ROICexc growth 5YN/A
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 1.6
Debt/EBITDA 0.69
Cap/Depr 254.79%
Cap/Sales 15.38%
Interest Coverage 250
Cash Conversion 111.33%
Profit Quality 25.34%
Current Ratio 5.08
Quick Ratio 4.97
Altman-Z 4.22
F-Score6
WACC7.68%
ROIC/WACC0.89
Cap/Depr(3y)113.33%
Cap/Depr(5y)77.81%
Cap/Sales(3y)6.8%
Cap/Sales(5y)4.77%
Profit Quality(3y)120.06%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.47%
EBIT growth 3Y25.85%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.16%
FCF growth 3Y-0.7%
FCF growth 5Y47.39%
OCF growth 1Y42.74%
OCF growth 3Y17.98%
OCF growth 5Y59.75%